Benzinga | Dec 21, 2021 08:02AM EST

Certara Announces FDA Renewal And Expansion Of Certara's Biosimulation Software For Reviewing Regulatory Submissions

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara's proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software. In total, there are 12 divisions and offices of the FDA using Certara's software for internal research and to independently analyze, verify and review regulatory submissions.